Semaglutide vs Survodutide
A side-by-side research comparison of Semaglutide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Semaglutide | Survodutide |
|---|---|---|
| Full name | Semaglutide (GLP-1 Receptor Agonist) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA Approved | Phase 3 Clinical Trial |
| Mechanism | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 4,114 Da | 4,500 Da (approximate) |
| Half-life | 7 days (168 hours) | 5-7 days |
| Bioavailability | High (SubQ ~89%), Moderate (oral ~1% with SNAC) | High (SubQ) |
| Typical dose | 0.25 mg → titrate up to 2.4 mg | 0.6-6.0 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection | Subcutaneous |
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.